[Ip-health] A Russian court grants a compulsory license for a best-selling Celgene drug

James Love james.love at keionline.org
Tue Jul 10 13:55:40 PDT 2018


https://www.statnews.com/pharmalot/2018/07/10/russia-celgene-compulsory-license/

A Russian court grants a compulsory license for a best-selling Celgene drug

By ED SILVERMAN @Pharmalot JULY 10, 2018

In an unusual move, a Moscow court has granted a compulsory license to a
domestic company that plans to make and sell a version of a best-selling
Celgene (CELG) medicine. And tucked into the decision was a reference to
promoting public health, a stance that was reiterated this week by a
Russian delegate to a United Nations forum on patents, according to one
attendee.

At issue is Revlimid, a blockbuster cancer drug that generated $8.2 billion
in worldwide sales in 2017 for Celgene. The biotech last year filed a
lawsuit against a Russian company called Nativa to ban production and sales
of a copycat version. But last month an arbitration court sided with
Nativa, which plans to sell its version for 20 percent to 66 percent less,
depending upon the dose, a company spokeswoman wrote us.

Story
​
Continues
​
behind
​
paywall



--
James Love.  Knowledge Ecology International
http://www.keionline.org/donate.html
KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
+41.76.413.6584, twitter.com/jamie_love


More information about the Ip-health mailing list